WallStreetZenWallStreetZen

NASDAQ: GEVO
Gevo Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for GEVO

Based on 1 analyst offering 12 month price targets for Gevo Inc

Min Forecast
$2.25-3.43%
Avg Forecast
$2.25-3.43%
Max Forecast
$2.25-3.43%

Should I buy or sell GEVO stock?

Based on 1 analyst offering ratings for Gevo Inc.

Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
1 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model agrees with analyst consensus with a "Hold" rating. Learn More

Be the first to know when Wall Street analysts revise their GEVO stock forecasts and price targets.

GEVO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-09-17

1 of 1

Forecast return on equity

Is GEVO forecast to generate an efficient return?

Company
7.38%
Industry
35.69%
Market
229.18%
GEVO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is GEVO forecast to generate an efficient return on assets?

Company
5.05%
Industry
11.62%
GEVO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

GEVO earnings per share forecast

What is GEVO's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$0.21
Avg 2 year Forecast
-$0.20
Avg 3 year Forecast
-$0.19

GEVO revenue forecast

What is GEVO's revenue in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
$173.9M+43.77%
Avg 2 year Forecast
$194.7M+61.03%
Avg 3 year Forecast
$202.3M+67.28%
GEVO's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

GEVO revenue growth forecast

How is GEVO forecast to perform vs Specialty Chemicals companies and vs the US market?

Company
19.2%
Industry
4.63%
Market
25.64%
GEVO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
GEVO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

GEVO vs Specialty Chemical Stocks

TickerPricePrice TargetUp/downsideConsensus
GEVO$2.33$2.25-3.43%Hold
KRO$4.88$6.00+22.95%Strong Sell
KOP$29.20$52.50+79.79%Strong Buy
LWLG$4.03N/AN/A
MATV$12.18N/AN/A
View Top Specialty Chemical Stocks

Gevo Stock Forecast FAQ

Is Gevo Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: GEVO) stock is to Hold GEVO stock.

Out of 1 analyst, 0 (0%) are recommending GEVO as a Strong Buy, 0 (0%) are recommending GEVO as a Buy, 1 (100%) are recommending GEVO as a Hold, 0 (0%) are recommending GEVO as a Sell, and 0 (0%) are recommending GEVO as a Strong Sell.

If you're new to stock investing, here's how to buy Gevo stock.

What is GEVO's earnings growth forecast for 2025-2027?

(NASDAQ: GEVO) Gevo's forecast annual earnings growth rate of N/A is not forecast to beat the US Specialty Chemicals industry's average forecast earnings growth rate of 10.77%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.83%.

Gevo's earnings in 2025 is -$45,145,000.On average, 5 Wall Street analysts forecast GEVO's earnings for 2025 to be -$50,254,846, with the lowest GEVO earnings forecast at -$75,988,042, and the highest GEVO earnings forecast at -$33,075,152. On average, 5 Wall Street analysts forecast GEVO's earnings for 2026 to be -$48,607,146, with the lowest GEVO earnings forecast at -$83,111,920, and the highest GEVO earnings forecast at -$5,088,485.

In 2027, GEVO is forecast to generate -$46,959,447 in earnings, with the lowest earnings forecast at -$97,359,678 and the highest earnings forecast at $5,088,485.

What is GEVO's revenue growth forecast for 2025-2027?

(NASDAQ: GEVO) Gevo's forecast annual revenue growth rate of 19.2% is forecast to beat the US Specialty Chemicals industry's average forecast revenue growth rate of 4.63%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.64%.

Gevo's revenue in 2025 is $120,932,000.On average, 7 Wall Street analysts forecast GEVO's revenue for 2025 to be $42,127,809,011, with the lowest GEVO revenue forecast at $38,136,982,976, and the highest GEVO revenue forecast at $47,831,758,304. On average, 7 Wall Street analysts forecast GEVO's revenue for 2026 to be $47,187,216,880, with the lowest GEVO revenue forecast at $43,232,737,167, and the highest GEVO revenue forecast at $52,411,394,738.

In 2027, GEVO is forecast to generate $49,019,071,454 in revenue, with the lowest revenue forecast at $45,629,171,258 and the highest revenue forecast at $51,648,121,999.

What is GEVO's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: GEVO) forecast ROA is 5.05%, which is lower than the forecast US Specialty Chemicals industry average of 11.62%.

What is GEVO's Price Target?

According to 1 Wall Street analyst that have issued a 1 year GEVO price target, the average GEVO price target is $2.25, with the highest GEVO stock price forecast at $2.25 and the lowest GEVO stock price forecast at $2.25.

The Wall Street analyst predicted that Gevo's share price could fall to $2.25 by Sep 17, 2026. The average Gevo stock price prediction forecasts a potential downside of 3.43% from the current GEVO share price of $2.33.

What is GEVO's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: GEVO) Gevo's current Earnings Per Share (EPS) is -$0.20. On average, analysts forecast that GEVO's EPS will be -$0.21 for 2025, with the lowest EPS forecast at -$0.31, and the highest EPS forecast at -$0.14. On average, analysts forecast that GEVO's EPS will be -$0.20 for 2026, with the lowest EPS forecast at -$0.34, and the highest EPS forecast at -$0.02. In 2027, GEVO's EPS is forecast to hit -$0.19 (min: -$0.40, max: $0.02).

What is GEVO's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: GEVO) forecast ROE is 7.38%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.